Get to know our clinical trials
Extension clinical trial to evaluate the long-term safety and efficacy of afimkibart (RO7790121) in patients with atopic dermatitis who participated in previous clinical trials with afimkibart.
THE PURPOSE OF THIS TRIAL IS TO CONTINUE EVALUATING WHETHER THE INVESTIGATIONAL DRUG AFIMKIBART, WHEN ADMINISTERED OVER A LONGER PERIOD, IS SAFE AND EFFECTIVE FOR MODERATE-TO-SEVERE ATOPIC DERMATITIS, AND TO DETERMINE THE LONG-TERM EFFECTS, BOTH POSITIVE AND NEGATIVE, OF AFIMKIBART ON ATOPIC DERMATITIS. YOU ARE BEING ASKED TO PARTICIPATE IN THIS TRIAL BECAUSE YOU HAVE MODERATE-TO-SEVERE ATOPIC DERMATITIS, PARTICIPATED IN STUDY CS45570, AND RESPONDED TO TREATMENT WITH AFIMKIBART.
Technical Summary
- EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF AFIMKIBART (RO7790121) IN PATIENTS WITH ATOPIC DERMATITIS WHO PARTICIPATED IN PREVIOUS CLINICAL TRIALS WITH AFIMKIBART.
- Code EudraCT: 2025-520771-59-00
- Protocol number: CS45943
- Promoter: F. Hoffmann-La Roche Ltd.
- Molecule/Drug: Afimkibart
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.